In a new study, adding an individualized mRNA-based vaccine to post-surgery pembrolizumab immunotherapy for high-risk melanoma reduced the risk of melanoma recurrence or death by 42% compared with pembrolizumab alone. The findings were announced in a presentation at the ESMO (European Society for Medical Oncology) Congress 2026 in Madrid. According to a press release from the Melanoma Institute Australia, positive results in melanoma suggest this personalized approach may ena

Dr. Antoni Ribas, senior author of the study and director of the UCLA Health Jonsson Comprehensive Cancer Center’s Tumour Immunology...

Data from a Phase 2b study indicates that an investigational personalized mRNA cancer vaccine known as mRNA-4157/V940, in combination...

The immunotherapy medication pembrolizumab, approved for the treatment of stage III and IV melanoma, has been shown to reduce...

A proof-of-principle study has found that fecal transplants may help advanced melanoma patients respond to immunotherapy better.